Correlation Between NLS Pharmaceutics and Entera Bio

Can any of the company-specific risk be diversified away by investing in both NLS Pharmaceutics and Entera Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NLS Pharmaceutics and Entera Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NLS Pharmaceutics AG and Entera Bio, you can compare the effects of market volatilities on NLS Pharmaceutics and Entera Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NLS Pharmaceutics with a short position of Entera Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of NLS Pharmaceutics and Entera Bio.

Diversification Opportunities for NLS Pharmaceutics and Entera Bio

0.62

Correlation Coefficient

NLS Pharmaceutics  Entera Bio

Poor diversification

The 3 months correlation between NLS and Entera is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding NLS Pharmaceutics AG and Entera Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entera Bio and NLS Pharmaceutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NLS Pharmaceutics AG are associated (or correlated) with Entera Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entera Bio has no effect on the direction of NLS Pharmaceutics i.e., NLS Pharmaceutics and Entera Bio go up and down completely randomly.

Pair Corralation between NLS Pharmaceutics and Entera Bio

Given the investment horizon of 90 days NLS Pharmaceutics AG is expected to generate 2.11 times more return on investment than Entera Bio. However, NLS Pharmaceutics is 2.11 times more volatile than Entera Bio. It trades about 0.02 of its potential returns per unit of risk. Entera Bio is currently generating about -0.03 per unit of risk. If you would invest  182.00  in NLS Pharmaceutics AG on December 27, 2024 and sell it today you would lose (28.00) from holding NLS Pharmaceutics AG or give up 15.38% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	98.36%
Values	Daily Returns

NLS Pharmaceutics AG  vs.  Entera Bio

NLS Pharmaceutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in NLS Pharmaceutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, NLS Pharmaceutics may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Entera Bio

Risk-Adjusted Performance

Very Weak

Over the last 90 days Entera Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Pair Trading with NLS Pharmaceutics and Entera Bio

The main advantage of trading using opposite NLS Pharmaceutics and Entera Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NLS Pharmaceutics position performs unexpectedly, Entera Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will offset losses from the drop in Entera Bio's long position.

The idea behind NLS Pharmaceutics AG and Entera Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.